Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
HIV-1 envelope glycoprotein gp41 is a 345 amino acid transmembrane protein that plays a critical role in HIV-1 viral entry into host cells[3][4]. It can be segmented into three domains: an exposed ectodomain (amino acids 1-172), a transmembrane domain, and a cytoplasmic tail (CT) region (amino acids 195-345)[4]. The structure of gp41 is complex and undergoes significant conformational changes during the viral fusion process. In a free virion, the fusion peptides at the amino termini of gp41 are buried within the envelope complex in an inactive non-fusogenic state that is stabilized by a non-covalent bond with gp120[3]. When gp120 binds to CD4 and a co-receptor (CCR5 or CXCR4) on susceptible cells like Helper T cells and macrophages, it triggers a cascade of conformational changes in both gp120 and gp41 proteins[3]. Key structural elements of gp41 include: 1. **Fusion Peptide (FP)**: Highly conserved (84%) and involved in interaction with fusion inhibitors like T-20[4]. 2. **N-terminal Heptad Repeat (N-HR)**: Forms part of the six-helix bundle structure during fusion, highly conserved (86.2%)[4][5]. 3. **Fusion Peptide Proximal Region (FPPR)**: Well-conserved domain (84.9%) also implicated in interaction with fusion inhibitors[4]. 4. **Membrane-Proximal External Region (MPER)**: Highly conserved (84.2%) and plays a role in membrane fusion[1][4][5]. 5. **Transmembrane Domain (TMD)**: Forms an α-helical structure in membrane-mimicking environments and shows conformational flexibility[1][6]. 6. **Cytoplasmic Tail (CT)**: The least conserved domain despite its important role in envelope conformation and incorporation into budding viral particles[4]. During the fusion process, gp41 refolds into a six-helix bundle structure, bringing the viral and cellular membranes into close proximity[5][6]. This refolding process involves a coiled coil-to-lipid-embedded helix transition in MPER and reorientation of the C-terminal ectodomain[5]. The structure is cage-like with a hollow center that inhibits antibody access[3]. The trimerization specificity of native gp41 may reside in the MPER segment abutting the transmembrane anchor[5]. High-resolution NMR data has confirmed that the C-terminal segment of MPER and the TMD adopt α-helical structures in membrane-mimicking environments, with conformational flexibility around the transmembrane sequence[1].
Fusion inhibition (T-20 prevents the virus from entering the cell by binding to gp41 domains)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on HIV-1 envelope glycoprotein gp41 (gp41).